Mediwound Limited Ord (NASDAQ:MDWD) Shorts Decreased by 9.24% After Short Covering

February 15, 2018 - By Hazel Jackson

 Mediwound Limited Ord (NASDAQ:MDWD) Shorts Decreased by 9.24% After Short Covering

The stock of Mediwound Limited Ord (NASDAQ:MDWD) registered a decrease of 9.24% in short interest. MDWD’s total short interest was 123,700 shares in February as published by FINRA. Its down 9.24% from 136,300 shares, reported previously. With 36,400 shares average volume, it will take short sellers 3 days to cover their MDWD’s short positions. The short interest to Mediwound Limited Ord’s float is 1.21%.

The stock increased 2.41% or $0.1 during the last trading session, reaching $4.25. About 13,178 shares traded. MediWound Ltd. (NASDAQ:MDWD) has declined 11.84% since February 15, 2017 and is downtrending. It has underperformed by 28.54% the S&P500.

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products in Israel. The company has market cap of $114.95 million. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. It currently has negative earnings. The firm also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds.

MediWound Ltd. (NASDAQ:MDWD) Ratings Coverage

Among 7 analysts covering MediWound (NASDAQ:MDWD), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. MediWound had 18 analyst reports since August 10, 2015 according to SRatingsIntel. Oppenheimer maintained MediWound Ltd. (NASDAQ:MDWD) rating on Tuesday, October 17. Oppenheimer has “Buy” rating and $10.0 target. The rating was initiated by Wells Fargo on Wednesday, August 17 with “Outperform”. On Tuesday, June 27 the stock rating was maintained by Oppenheimer with “Buy”. Jefferies maintained MediWound Ltd. (NASDAQ:MDWD) on Thursday, August 24 with “Buy” rating. The firm earned “Buy” rating on Monday, June 12 by Jefferies. The stock of MediWound Ltd. (NASDAQ:MDWD) earned “Buy” rating by SunTrust on Thursday, November 16. The company was maintained on Thursday, November 16 by Oppenheimer. The company was initiated on Wednesday, March 23 by SunTrust. The rating was maintained by Oppenheimer on Thursday, July 20 with “Buy”. Jefferies maintained MediWound Ltd. (NASDAQ:MDWD) rating on Tuesday, September 26. Jefferies has “Buy” rating and $10.0 target.

More notable recent MediWound Ltd. (NASDAQ:MDWD) news were published by: Globenewswire.com which released: “Tel Aviv District Court Ordered MediWound to Purchase Approximately $1.5 …” on November 14, 2017, also Globenewswire.com with their article: “MediWound Successfully Completes Second Cohort of EscharEx® Phase 2 Study” published on September 01, 2017, Globenewswire.com published: “MediWound Announces Successful GMP Manufacturing Audit by the Israeli Ministry …” on May 03, 2017. More interesting news about MediWound Ltd. (NASDAQ:MDWD) were released by: Globenewswire.com and their article: “MediWound Announces Exercise of Underwriters’ Option to Purchase Additional Shares” published on October 27, 2017 as well as Seekingalpha.com‘s news article titled: “MediWound: Doubling Sales Even Before Likely FDA Approval” with publication date: November 22, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.